Udvalget besluttede derfor, at fordelene ved Zomarist er større end risiciene ved behandling af patienter med type 2 - diabetes mellitus, hvor der ikke kan opnås tilstrækkelig glykæmisk kontrol trods indtagelse af den maksimale daglige orale dosis af metformin alene, eller som allerede behandles med en kombination af vildagliptin og metformin som enkelttabletter.
Therefore, the Committee decided that the benefits of Zomarist are greater than its risks for the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.